Evidence map›Paper›PMID 25052452›Full record

ArticleThe oncologist2014

Sorafenib in thyroid cancer patients: learning from toxicity.

Olivier Huillard, Benoit Blanchet, Pascaline Boudou-Rouquette, Audrey Thomas-Schoemann, Johanna Wassermann, François Goldwasser

Open access · bronzeAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Olivier HuillardMedical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
Benoit BlanchetPharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
Pascaline Boudou-RouquetteMedical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
Audrey Thomas-SchoemannPharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP and UMR 8638 CNRS, Faculty of Pharmacy, Paris Pharmaceutical Research Center, Paris Descartes University, Paris, France.
Johanna WassermannMedical Oncology Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre et Marie Curie University, Paris, France.
François GoldwasserMedical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Cochin Hospital, AP-HP, Paris Descartes University, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRHôpital Cochin · FRSorbonne Université · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsFemaleHumansMaleNiacinamidePhenylurea CompoundsThyroid NeoplasmsAntineoplastic AgentsNiacinamidePhenylurea Compounds

Identifiers

PMID25052452
PMCPMC4122476
OpenAlexW2155885164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.